Veeva vs. Salesforce: Which Life Sciences CRM Stock Is the Better Buy?
The split sets up a compelling faceoff between two companies now heading down very different paths. Veeva is sharpening its focus on life sciences by building vertically integrated solutions tailored to the sector's needs. At the same time, Salesforce is making a deliberate push into life sciences with its own purpose-built CRM offering. Both companies are accelerating investments in AI and product innovation, but their visions for capturing long-term growth are rapidly diverging. For investors, the key question is which company offers the stronger roadmap in this evolving market.
Price Performance & Valuation of VEEV & CRM
Shares of Veeva have gained 35.7%, while CRM stock has plunged 21.1% in the year-to-date period.
From a valuation standpoint, CRM looks slightly more attractive than VEEV. According to the price-to-book ratio, Salesforce's shares currently trade at 4.15X, which is lower than Veeva's 7.50X.
Platform Control & Industry Focus: Who Owns the Vertical?
Veeva has long differentiated itself by serving a single industry—life sciences—with laser focus. That specialization is now reaching a new level as the company prepares to fully shift its CRM operations from Salesforce's infrastructure to its own Vault platform by September 2025. This move is more than just a tech transition. It gives Veeva full control over its software stack, allowing it to tailor features, optimize performance, and potentially expand margins without depending on a third-party host. More importantly, it strengthens Veeva's position as a vertically integrated player with deep regulatory and workflow understanding, something horizontal platforms often struggle to replicate in niche markets.
Salesforce, meanwhile, brings the power of a highly adaptable and proven CRM infrastructure that serves thousands of enterprise customers across industries. Its recent push into life sciences through the introduction of a dedicated Life Sciences Cloud reflects a strategic intent to expand within this high-value vertical. While its approach is broader by design, Salesforce benefits from scale, flexibility, and a robust ecosystem that supports rapid customization through its platform tools. With the partnership ending, Salesforce now has the freedom to compete directly in life sciences CRM, and its entry could accelerate innovation and choice in the market without being constrained by a single client relationship.
AI & Product Innovation: Whose Tech Vision Leads?
Veeva is taking a focused approach to AI by building capabilities directly into its Vault platform. In April 2025, it launched Veeva AI, which integrates LLM agents and shortcuts across clinical, regulatory, and commercial apps. Features like Vault CRM Bot, Voice Control, and MLR Bot are set to roll out by late 2025, automating tasks such as pre-call planning and content compliance. Veeva also released the Direct Data API to enable faster, secure access to Vault data, supporting integrations with platforms like Snowflake and Databricks. These innovations are already gaining traction, with over 80 Vault CRM deployments and a goal of exceeding 200 by fiscal 2026.
Salesforce is advancing AI at scale through Agentforce, a platform of prebuilt AI assistants embedded across its suite. Within 90 days of launch, Agentforce reached 3,000 paying customers and crossed $100 million in ARR. It connects with Tableau, MuleSoft, and Data Cloud to unify workflows and supports the Life Sciences Cloud Partner Network, which includes integrations with H1, ComplianceQuest, Box, and others. The company has also brought on AI-focused board members and continues to emphasize responsible adoption, aiming to augment human roles rather than replace them.
The Road Ahead: Who's Better Positioned for CRM Leadership in Life Sciences?
Veeva is focused on finalizing its shift to the Vault platform, aiming to boost margins and accelerate innovation with full control over its tech stack. Its AI roadmap, including tools like Vault CRM Bot and Voice Control, is designed to enhance productivity and compliance for life sciences users. With strong early adoption of Vault CRM and expanding enterprise relationships, Veeva is positioning itself as the go-to vertical platform for the sector.
Salesforce is pursuing growth through its broad platform and expanding presence in life sciences via its dedicated cloud and AI-led offerings. Backed by a strong ecosystem and new integrations with healthcare partners, Salesforce is embedding Agentforce AI across its products. Its scale, flexibility, and ability to serve complex enterprise needs provide a strong foundation as it targets more specialized verticals like life sciences.
How Do Zacks Estimates Compare for VEEV & CRM?
The Zacks Consensus Estimate for VEEV's fiscal 2026 sales implies a year-over-year growth of 12.78%. For fiscal 2026, the earnings per share are projected to be $7.64, up 15.76% year over year. The earnings estimates have been trending upward over the past 60 days.
The Zacks Consensus Estimate for CRM's fiscal 2026 sales and earnings implies year-over-year growth of 8.64% and 10.78%, respectively. The earnings estimates have been trending upward over the past 60 days.
VEEV or CRM: Which Is the Smarter Buy?
Veeva and Salesforce represent two powerful but contrasting approaches to the life sciences CRM market—one focused on deep vertical integration, the other leveraging broad enterprise reach. Veeva currently holds a Zacks Rank #2 (Buy), reflecting positive sentiment and growing confidence in its post-Salesforce roadmap. Its Growth Score of 'A' highlights strong potential in revenue acceleration, margin expansion, and product adoption. Salesforce, meanwhile, carries a Zacks Rank #3 (Hold) but also maintains a Growth Score of 'A', supported by its scale, product breadth, and AI-led innovation strategy. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Both companies are positioned for long-term relevance, but Veeva's focused strategy, platform control, and growing traction in life sciences give it the edge for investors seeking targeted exposure in this vertical. Salesforce remains a strong contender with scale and innovation, yet Veeva's clarity and execution make it the more compelling pick in this CRM faceoff.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Salesforce Inc. (CRM): Free Stock Analysis Report
Veeva Systems Inc. (VEEV): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
Why Blue Bird Stock Soared More Than 27% Higher This Week
Key Points The veteran bus maker delivered a quarter for the ages. It notched new all-time highs in key fundamentals. 10 stocks we like better than Blue Bird › A beat-and-raise fiscal third quarter was the fuel driving Blue Bird (NASDAQ: BLBD) stock forward this week. Thanks mostly to this the company's shares motored over 27% higher during the period, according to data compiled by S&P Global Market Intelligence. Blue's success with yellow That three-month period saw Blue Bird, a longtime manufacturer of school buses, hit new highs for both quarterly revenue and profitability. The former line item zoomed 19% higher to $398 million, while non-GAAP (adjusted) net income improved by more than 26% to $38.7 million ($1.19 per share). Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Analysts were expecting the quarter to be profitable, but not this profitable. As a group they were modeling only $1 per share for adjusted net income. They also underestimated revenue, as they predicted less than $378 million. Although it's identified -- if at all -- with the traditional gas-guzzling yellow school buses, Blue Bird has been busily upgrading its signature product over the years. It has pushed assertively into the alternative-fuel space, embracing greener solutions such as electric vehicle (EV) technology. In its earnings release, Blue Bird referred to "expanding its leadership" in such alt-fuel offerings. It also mentioned that it was able to successfully side-step many of the tariffs recently imposed by the Trump administration, among other results-boosting factors. A lift in guidance With that solid quarter at its back, Blue Bird felt confident enough to raise its full-year-2025 guidance. The company now expects to earn roughly $1.45 billion in revenue and post an adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) figure of $205 million to $215 million. It did not provide a net income estimate. Should you invest $1,000 in Blue Bird right now? Before you buy stock in Blue Bird, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Blue Bird wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,563!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,108,033!* Now, it's worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025
CBC
3 hours ago
- CBC
U.S. increases softwood lumber fees on Canada to 35.19%
The U.S. Department of Commerce increased countervailing duties on Canadian softwood lumber on Friday, bringing the total to 35.19 per cent.
Globe and Mail
6 hours ago
- Globe and Mail
Energy Transfer's Mixed Q2 2025 Earnings Call Insights
Energy Transfer Equity ((ET)) has held its Q2 earnings call. Read on for the main highlights of the call. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Energy Transfer's recent earnings call painted a mixed picture of the company's financial health. While the company celebrated record EBITDA and announced significant new projects, particularly in the natural gas sector, there were also areas of concern. Segments like NGL and crude oil experienced declines, and the adjusted guidance due to weaker than anticipated performance in certain areas suggests a cautious outlook. Record Adjusted EBITDA Energy Transfer reported an adjusted EBITDA of $3.9 billion for Q2 2025, marking an increase from $3.8 billion in Q2 2024. This growth trend highlights the company's robust financial performance, despite challenges in some segments. Desert Southwest Pipeline Project In a significant development, Energy Transfer announced a new 516-mile, 42-inch pipeline project. This $5.3 billion investment is expected to enhance system reliability by transporting 1.5 Bcf/day from the Permian Basin to Phoenix, Arizona, underscoring the company's commitment to expanding its infrastructure. Permian Basin Processing Expansion The successful commissioning of the Lenorah II and Badger processing plants has led to record processing volumes of nearly 5 Bcf/day. This expansion in the Permian Basin is a testament to Energy Transfer's strategic focus on increasing capacity and efficiency. Lake Charles LNG Project Progress Energy Transfer has made substantial progress with the Lake Charles LNG project. The company has secured HOAs with MidOcean Energy and long-term SPAs with Kyushu Electric Power Company and Chevron USA, indicating strong demand and strategic partnerships. Hyperscaler Agreement for Data Centers In a move to boost its gas supply capabilities, Energy Transfer signed a significant agreement with a hyperscaler. This agreement increases the gas supply from 80,000 to 380,000 a day, with potential for further growth, highlighting the company's adaptability and forward-thinking approach. NGL and Refined Products EBITDA Decline The NGL and refined products segment reported a decline in adjusted EBITDA to $1 billion from $1.1 billion in Q2 2024. This decrease was attributed to lower gains from the optimization of hedged NGL and refined product inventories, reflecting challenges in this segment. Crude Oil Segment Revenue Decline The crude oil segment also faced challenges, with adjusted EBITDA falling to $732 million from $801 million in Q2 2024. This decline was mainly due to lower transportation revenues on the Bakken pipeline, indicating a need for strategic adjustments. Guidance Adjustment Energy Transfer adjusted its guidance to be at or slightly below the lower end of the range of $16.1 billion to $16.5 billion. This adjustment reflects weaker than expected performance in the Bakken and Permian crude businesses, highlighting the company's cautious outlook for the future. In conclusion, Energy Transfer's earnings call revealed a company navigating through both achievements and challenges. While there is optimism with record EBITDA and new projects, the declines in certain segments and adjusted guidance suggest a need for strategic focus and adaptability. Investors will be keen to see how Energy Transfer addresses these challenges moving forward.
